Telix Pharmaceuticals (TLX) Stock Price, Fundamentals & Analysis

What TLX does

Telix Pharmaceuticals (TLX) is a commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, that develops and commercializes therapeutic and diagnostic radiopharmaceuticals. It operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic candidate, TLX591, is a lutetium-labeled radio antibody-drug conjugate in a Phase 3 trial for advanced prostate cancer; other candidates include TLX250 for metastatic kidney cancer, TLX101 for glioblastoma, TLX66 for bone marrow conditioning, and Illuccix and Gozellix for prostate cancer treatment. The stock trades on the ASX and is part of the ASX 200.

Key numbers explained

• 15,9 AUD is the current share price, the amount you would pay for one share right now.
• +1,02% is today's price change, showing the percentage move relative to the previous close.
• The trailing P/E ratio of 113,6 divides the current price by the last 12 months' earnings per share; a high number can mean the market expects strong future growth or that recent earnings were unusually low.
• The forward P/E ratio of -10.192,3 uses expected future earnings; a negative value typically signals that the market expects a loss or that earnings are not yet reliably forecast.
• Dividend yield is 0%, meaning the company currently pays no cash dividend to shareholders.
• Beta of 0,6 suggests the stock has historically moved about 60% as much as the broader market, indicating lower volatility.
• 5,39 mld. AUD is the market capitalization, the total value of all outstanding shares.
• 8,26 – 18,22 is the 52-week price range, showing the lowest and highest traded prices over the past year.

What to watch

• Clinical trial results for TLX591 and other candidates, which can shift sentiment in the biotechnology sector.
• Revenue growth of 22,3% year over year and the path toward sustained profitability, given a 3,8% profit margin.
• The company's capital structure, with a debt-to-equity ratio of 118,9%, which is higher than many peers and can affect risk perception.
• Comparisons with other healthcare names such as Ryman Healthcare (RYM), EBOS Group (EBO), and Sonic Healthcare (SHL), which operate in different parts of the healthcare ecosystem.
• The next earnings date, 19 aug. 2026, which is a common catalyst for price moves.